This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 2010 Mar;87(3):261-3.

doi: 10.1038/clpt.2009.294.

How innovative technology is moving biologics into the 21st century

D K Robinson¹, N Sethuraman

Affiliations

PMID: 20160744
DOI: 10.1038/clpt.2009.294

Review

How innovative technology is moving biologics into the 21st century

D K Robinson et al. Clin Pharmacol Ther. 2010 Mar.

. 2010 Mar;87(3):261-3.

doi: 10.1038/clpt.2009.294.

Authors

D K Robinson¹, N Sethuraman

Affiliation

¹ Department of Biologics Research, Merck Research Laboratories, Rahway, New Jersey, USA. David_K_Robinson@merck.com

PMID: 20160744
DOI: 10.1038/clpt.2009.294

No abstract available

PubMed Disclaimer

Similar articles

Current regulatory and legal considerations for follow-on biologics.
Kingham RF, Lietzan E. Kingham RF, et al. Clin Pharmacol Ther. 2008 Nov;84(5):633-5. doi: 10.1038/clpt.2008.159. Epub 2008 Aug 20. Clin Pharmacol Ther. 2008. PMID: 18716615 No abstract available.
Trends in development and approval times for new therapeutics in the United States.
Reichert JM. Reichert JM. Nat Rev Drug Discov. 2003 Sep;2(9):695-702. doi: 10.1038/nrd1178. Nat Rev Drug Discov. 2003. PMID: 12951576 Review.
Future development of harmonized guidelines.
Hayakawa T. Hayakawa T. Dev Biol Stand. 1996;88:331-2. Dev Biol Stand. 1996. PMID: 9119158 No abstract available.
The challenge of follow-on biologics for treatment of multiple sclerosis.
Reingold SC, Steiner JP, Polman CH, Cohen JA, Freedman MS, Kappos L, Thompson AJ, Wolinsky JS. Reingold SC, et al. Neurology. 2009 Aug 18;73(7):552-9. doi: 10.1212/WNL.0b013e3181b2a6ce. Neurology. 2009. PMID: 19687456 Review.
Safety issues specific to clinical development of protein therapeutics.
Haller CA, Cosenza ME, Sullivan JT. Haller CA, et al. Clin Pharmacol Ther. 2008 Nov;84(5):624-7. doi: 10.1038/clpt.2008.158. Epub 2008 Aug 13. Clin Pharmacol Ther. 2008. PMID: 18701885 No abstract available.

See all similar articles

Cited by

Immunobiologicals in dermatology.
Silva DLFD, Secamilli EN, Beleli MV, Massuda JY, Franca AFEC, Magalhães RF. Silva DLFD, et al. An Bras Dermatol. 2022 May-Jun;97(3):275-283. doi: 10.1016/j.abd.2021.05.016. Epub 2022 Mar 18. An Bras Dermatol. 2022. PMID: 35314083 Free PMC article.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wiley